MPL and essential thrombocythemia: MPL GOF mutations are collectively present in around 5–7% of ET and 7–10% of PMF patients [28], being a diagnostic criteria for both diseases [30], and are considerably more prevalent in those ET and PMF patients negative for JAK2 GOF mutations [28].